THERAPY DOSSIER · th-08cda2e6fc2f

XQ-1H (10-O-(N,N-dimethylaminoethyl)-ginkgolide B methanesulfonate)

Drug · XQ-1H, a ginkgolide-B methanesulfonate derivative / PAF receptor antagonist; not returned by ChEMBL (parent ginkgolide B has an early-phase trial but is a distinct entity).

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: XQ-1H, a ginkgolide-B methanesulfonate derivative / PAF receptor antagonist; not returned by ChEMBL (parent ginkgolide B has an early-phase trial but is a distinct entity).
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31499069 ↗2019Reported benefit

XQ-1H alleviates cerebral ischemia in mice through inhibition of apoptosis and promotion of neurogenesis in a Wnt/beta-catenin signaling dependent way.

MouseIschaemia-reperfusionCerebral (MCAO/stroke)MaleIntragastric78 or 39 mg/kgFirst dose 2 h after MCAO

Model: Middle cerebral artery occlusion with reperfusion (MCAO/R)

XQ-1H preserved motor function, reduced infarction and apoptosis, and promoted neurogenesis in the peri-infarct cortex, subventricular zone and dentate subgranular zone in a Wnt-dependent manner.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…